<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://articlefeeds.nasdaq.com/~d/styles/itemcontent.css"?><rss xmlns:a10="http://www.w3.org/2005/Atom" xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" version="2.0">
  <channel xmlns:nasdaq="http://nasdaq.com/reference/feeds/1.0/">
    <title>Latest Articles about SGEN</title>
    <description />
    <language>EN-US</language>
    <lastBuildDate>Sat, 18 May 2013 07:31:57 -0400</lastBuildDate>
    <atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://articlefeeds.nasdaq.com/nasdaq/symbols?symbol=SGEN" /><feedburner:info uri="nasdaq/symbols" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><item xml:base="http://www.nasdaq.com/article/sgens-adcetris-under-fda-review-analyst-blog-cm246767">
      <guid isPermaLink="false">246767</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/voEE_-VEUYo/sgens-adcetris-under-fda-review-analyst-blog-cm246767</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>SGEN's Adcetris under FDA Review - Analyst Blog</title>
      <description>Seattle Genetics, Inc.  (  SGEN  ) recently announced that the US Food and Drug Administration (FDA) has accepted its supplemental biologics license application (sBLA) seeking approval of&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/voEE_-VEUYo" height="1" width="1"/&gt;</description>
      <pubDate>Fri, 17 May 2013 00:29:37 Z</pubDate>
      <a10:updated>2013-05-16T21:31:52Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>ALKS</nasdaq:tickers>
      <nasdaq:tickers>ANIK</nasdaq:tickers>
      <nasdaq:tickers>HL</nasdaq:tickers>
      <nasdaq:tickers>MYGN</nasdaq:tickers>
      <nasdaq:tickers>SGEN</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/sgens-adcetris-under-fda-review-analyst-blog-cm246767</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/narrowerthanexpected-loss-at-seattle-genetics-analyst-blog-cm244591">
      <guid isPermaLink="false">244591</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ji1_gokERqI/narrowerthanexpected-loss-at-seattle-genetics-analyst-blog-cm244591</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Narrower-than-Expected Loss at Seattle Genetics  - Analyst Blog</title>
      <description>Seattle Genetics, Inc.  (  SGEN  ) reported first quarter 2013 net loss per share of 14 cents, narrower than the Zacks Consensus Estimate of a loss of 19 cents, but wider than the year-ago&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Ji1_gokERqI" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 08 May 2013 18:25:10 Z</pubDate>
      <a10:updated>2013-05-08T15:25:57Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>BIIB</nasdaq:tickers>
      <nasdaq:tickers>HL</nasdaq:tickers>
      <nasdaq:tickers>RHHBY</nasdaq:tickers>
      <nasdaq:tickers>SGEN</nasdaq:tickers>
      <nasdaq:tickers>TSPT</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/narrowerthanexpected-loss-at-seattle-genetics-analyst-blog-cm244591</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/pharmacyclics-inc-pcyc-todays-most-compelling-stock-buy-cm244319">
      <guid isPermaLink="false">244319</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RCW3s1Ld2Ow/pharmacyclics-inc-pcyc-todays-most-compelling-stock-buy-cm244319</link>
      <category>Investing</category>
      <category>Investing Ideas</category>
      <category>Stocks</category>
      <category>US Markets</category>
      <title>Pharmacyclics Inc. (PCYC): Today's Most Compelling Stock Buy</title>
      <description>           SoTM Bull's Eye Report - Today's Most Compelling Buy       Tuesday, May 7, 2013          At  StateoftheMarkets.com , we strive to "own the best and ignore the&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/RCW3s1Ld2Ow" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 07 May 2013 21:53:41 Z</pubDate>
      <a10:updated>2013-05-07T17:53:44Z</a10:updated>
      <author>David Moenning</author>
      <nasdaq:tickers>MDVN</nasdaq:tickers>
      <nasdaq:tickers>ONXX</nasdaq:tickers>
      <nasdaq:tickers>PCYC</nasdaq:tickers>
      <nasdaq:tickers>SGEN</nasdaq:tickers>
      <nasdaq:tickers>XBI</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/pharmacyclics-inc-pcyc-todays-most-compelling-stock-buy-cm244319</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/polycyclics-inc-pcyc-todays-most-compelling-stock-pick-cm241222">
      <guid isPermaLink="false">241222</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lT8kLbFIDnQ/polycyclics-inc-pcyc-todays-most-compelling-stock-pick-cm241222</link>
      <category>Investing</category>
      <category>Investing Ideas</category>
      <category>Stocks</category>
      <category>US Markets</category>
      <title>Polycyclics Inc. (PCYC): Today's Most Compelling Stock Pick</title>
      <description>           SoTM Bull's Eye Report - Today's Most Compelling Buy       Friday, April 26, 2013          At  StateoftheMarkets.com , we strive to "own the best and ignore the&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/lT8kLbFIDnQ" height="1" width="1"/&gt;</description>
      <pubDate>Fri, 26 Apr 2013 23:20:21 Z</pubDate>
      <a10:updated>2013-04-26T19:20:24Z</a10:updated>
      <author>David Moenning</author>
      <nasdaq:tickers>MDVN</nasdaq:tickers>
      <nasdaq:tickers>ONXX</nasdaq:tickers>
      <nasdaq:tickers>PCYC</nasdaq:tickers>
      <nasdaq:tickers>SGEN</nasdaq:tickers>
      <nasdaq:tickers>XBI</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/polycyclics-inc-pcyc-todays-most-compelling-stock-pick-cm241222</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/astellas-ambrx-tieup-on-adc-analyst-blog-cm234306">
      <guid isPermaLink="false">234306</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cVVtsrJv8oM/astellas-ambrx-tieup-on-adc-analyst-blog-cm234306</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Astellas, Ambrx Tie-Up on ADC - Analyst Blog</title>
      <description>Astellas Pharma, Inc.  (  ALPMY  ) recently announced a deal with Ambrx Inc. for the discovery and development of novel antibody drug conjugates (ADC).   Terms of the Deal   As per the&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/cVVtsrJv8oM" height="1" width="1"/&gt;</description>
      <pubDate>Sat, 06 Apr 2013 02:09:26 Z</pubDate>
      <a10:updated>2013-04-05T23:13:25Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>ADC</nasdaq:tickers>
      <nasdaq:tickers>ALPMY</nasdaq:tickers>
      <nasdaq:tickers>RHHBY</nasdaq:tickers>
      <nasdaq:tickers>SGEN</nasdaq:tickers>
      <nasdaq:tickers>WX</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/astellas-ambrx-tieup-on-adc-analyst-blog-cm234306</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/takeda-files-adcetris-in-japan-analyst-blog-cm231460">
      <guid isPermaLink="false">231460</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h669EYArkSc/takeda-files-adcetris-in-japan-analyst-blog-cm231460</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Takeda Files Adcetris in Japan - Analyst Blog</title>
      <description>Takeda Pharmaceutical Company Limited  (  TKPYY  ) and its subsidiary, Millennium, recently announced the submission of a new drug application (NDA) to the Ministry of Health, Labour and&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/h669EYArkSc" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 27 Mar 2013 23:26:29 Z</pubDate>
      <a10:updated>2013-03-27T20:29:01Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CYTK</nasdaq:tickers>
      <nasdaq:tickers>HL</nasdaq:tickers>
      <nasdaq:tickers>LCI</nasdaq:tickers>
      <nasdaq:tickers>SGEN</nasdaq:tickers>
      <nasdaq:tickers>TKPYY</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/takeda-files-adcetris-in-japan-analyst-blog-cm231460</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/sgen-seeks-adcetris-label-expansion-analyst-blog-cm228763">
      <guid isPermaLink="false">228763</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AkZXt8MuEDg/sgen-seeks-adcetris-label-expansion-analyst-blog-cm228763</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>SGEN Seeks Adcetris Label Expansion - Analyst Blog</title>
      <description>Seattle Genetics, Inc.  (  SGEN  ) recently announced the submission of a supplemental biologics license application (sBLA) to the US Food and Drug Administration (FDA) for the use of Adcetris&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/AkZXt8MuEDg" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 20 Mar 2013 03:15:01 Z</pubDate>
      <a10:updated>2013-03-20T00:46:31Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CYTK</nasdaq:tickers>
      <nasdaq:tickers>HL</nasdaq:tickers>
      <nasdaq:tickers>OSIR</nasdaq:tickers>
      <nasdaq:tickers>SGEN</nasdaq:tickers>
      <nasdaq:tickers>XOMA</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/sgen-seeks-adcetris-label-expansion-analyst-blog-cm228763</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/sgen-narrows-loss-sales-rise-analyst-blog-cm217265">
      <guid isPermaLink="false">217265</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sak9a17n_pE/sgen-narrows-loss-sales-rise-analyst-blog-cm217265</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>SGEN Narrows Loss, Sales Rise - Analyst Blog</title>
      <description>Seattle Genetics, Inc.  (  SGEN  ) reported fourth quarter 2012 net loss per share of 9 cents, narrower than the Zacks Consensus Estimate of a loss of 13 cents and the year-ago loss of 24&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/sak9a17n_pE" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 13 Feb 2013 19:58:01 Z</pubDate>
      <a10:updated>2013-02-13T16:51:42Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>CBM</nasdaq:tickers>
      <nasdaq:tickers>CYTK</nasdaq:tickers>
      <nasdaq:tickers>HL</nasdaq:tickers>
      <nasdaq:tickers>SGEN</nasdaq:tickers>
      <nasdaq:tickers>TRGT</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/sgen-narrows-loss-sales-rise-analyst-blog-cm217265</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/afterhours-earnings-report-for-february-12-2013-fti-rax-wu-frt-wsh-ddr-clf-acc-hcc-gwr-sgen-skt-cm216903">
      <guid isPermaLink="false">216903</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Exx6ijuXjK8/afterhours-earnings-report-for-february-12-2013-fti-rax-wu-frt-wsh-ddr-clf-acc-hcc-gwr-sgen-skt-cm216903</link>
      <category>News Headlines</category>
      <category>Earnings</category>
      <title>After-Hours Earnings Report for February 12, 2013 :  FTI, RAX, WU, FRT, WSH, DDR, CLF, ACC, HCC, GWR, SGEN, SKT</title>
      <description>The following companies are expected to report earnings after hours on 02/12/2013. Visit our  Earnings Calendar  for a full list of expected earnings releases.   FMC Technologies, Inc.  (  FTI  )&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/Exx6ijuXjK8" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 13 Feb 2013 00:00:04 Z</pubDate>
      <a10:updated>2013-02-12T19:24:50Z</a10:updated>
      <author>NASDAQ.com News</author>
      <nasdaq:tickers>ACC</nasdaq:tickers>
      <nasdaq:tickers>CLF</nasdaq:tickers>
      <nasdaq:tickers>DDR</nasdaq:tickers>
      <nasdaq:tickers>FRT</nasdaq:tickers>
      <nasdaq:tickers>FTI</nasdaq:tickers>
      <nasdaq:tickers>GWR</nasdaq:tickers>
      <nasdaq:tickers>HCC</nasdaq:tickers>
      <nasdaq:tickers>RAX</nasdaq:tickers>
      <nasdaq:tickers>SGEN</nasdaq:tickers>
      <nasdaq:tickers>SKT</nasdaq:tickers>
      <nasdaq:tickers>WSH</nasdaq:tickers>
      <nasdaq:tickers>WU</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/afterhours-earnings-report-for-february-12-2013-fti-rax-wu-frt-wsh-ddr-clf-acc-hcc-gwr-sgen-skt-cm216903</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/canada-approves-seattle-genetics-adcetris-analyst-blog-cm213857">
      <guid isPermaLink="false">213857</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F9vcQ1L8GRI/canada-approves-seattle-genetics-adcetris-analyst-blog-cm213857</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Canada Approves Seattle Genetics' Adcetris - Analyst Blog</title>
      <description>Seattle Genetics Inc.  (  SGEN  ) recently received approval from Health Canada for its oncology drug, Adcetris (brentuximab vedotin). Adcetris has been approved under Health Canada's Notice&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/F9vcQ1L8GRI" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 05 Feb 2013 03:44:21 Z</pubDate>
      <a10:updated>2013-02-04T23:48:37Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>HL</nasdaq:tickers>
      <nasdaq:tickers>PPHM</nasdaq:tickers>
      <nasdaq:tickers>SGEN</nasdaq:tickers>
      <nasdaq:tickers>TRGT</nasdaq:tickers>
      <nasdaq:tickers>VRX</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/canada-approves-seattle-genetics-adcetris-analyst-blog-cm213857</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/data-from-sgen-on-cancer-candidate-analyst-blog-cm211874">
      <guid isPermaLink="false">211874</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gAXTqF9NBXI/data-from-sgen-on-cancer-candidate-analyst-blog-cm211874</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Data From SGEN on Cancer Candidate  - Analyst Blog</title>
      <description>Seattle Genetics, Inc.  (  SGEN  ) recently presented interim results from a phase I study which is evaluating ASG-5ME for the treatment of metastatic pancreatic ductal adenocarcinoma (PDA).&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/gAXTqF9NBXI" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 29 Jan 2013 23:00:01 Z</pubDate>
      <a10:updated>2013-01-29T19:25:03Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>ADC</nasdaq:tickers>
      <nasdaq:tickers>ALPMY</nasdaq:tickers>
      <nasdaq:tickers>MTD</nasdaq:tickers>
      <nasdaq:tickers>SGEN</nasdaq:tickers>
      <nasdaq:tickers>SLXP</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/data-from-sgen-on-cancer-candidate-analyst-blog-cm211874</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/sgentakedas-adcetris-progresses-analyst-blog-cm211040">
      <guid isPermaLink="false">211040</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7Bd5matbXfo/sgentakedas-adcetris-progresses-analyst-blog-cm211040</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>SGEN/Takeda's Adcetris Progresses - Analyst Blog</title>
      <description>Seattle Genetics Inc.  (  SGEN  ) and  Takeda Pharmaceutical Company Limited  (  TKPYY  ) recently announced the commencement of a global phase III study (ECHELON-2) on their oncology&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/7Bd5matbXfo" height="1" width="1"/&gt;</description>
      <pubDate>Sat, 26 Jan 2013 02:30:01 Z</pubDate>
      <a10:updated>2013-01-25T23:21:54Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>AGEN</nasdaq:tickers>
      <nasdaq:tickers>ASH</nasdaq:tickers>
      <nasdaq:tickers>SGEN</nasdaq:tickers>
      <nasdaq:tickers>SPA</nasdaq:tickers>
      <nasdaq:tickers>TKPYY</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/sgentakedas-adcetris-progresses-analyst-blog-cm211040</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/this-stock-could-be-perfect-for-the-dividend-decade-cm205238">
      <guid isPermaLink="false">205238</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1TWJ4WFMCds/this-stock-could-be-perfect-for-the-dividend-decade-cm205238</link>
      <category>Investing</category>
      <category>Investing Ideas</category>
      <category>Stocks</category>
      <title>This Stock Could be Perfect for the "Dividend Decade"</title>
      <description>If you're a regular StreetAuthority reader, then you've probably heard of the "dividend decade," a prediction that in the 10 years, therewill be no gain in the broadermarket .&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/1TWJ4WFMCds" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 08 Jan 2013 22:30:00 Z</pubDate>
      <a10:updated>2013-01-08T18:59:54Z</a10:updated>
      <author>Lisa Springer</author>
      <nasdaq:tickers>ABBV</nasdaq:tickers>
      <nasdaq:tickers>ABT</nasdaq:tickers>
      <nasdaq:tickers>GILD</nasdaq:tickers>
      <nasdaq:tickers>SGEN</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/this-stock-could-be-perfect-for-the-dividend-decade-cm205238</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/weekly-cfo-sells-highlight-sgen-pfie-mar-esrx-liox-rgen-cm171496">
      <guid isPermaLink="false">171496</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3V_7zcZuRvk/weekly-cfo-sells-highlight-sgen-pfie-mar-esrx-liox-rgen-cm171496</link>
      <category>Investing</category>
      <title>Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN</title>
      <description>According to  GuruFocus Insider Data  , the largest CFO sells during the past week were: Seattle Genetics Inc., Profire Energy Inc., Marriott International Inc, Express Scripts Holdings&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/3V_7zcZuRvk" height="1" width="1"/&gt;</description>
      <pubDate>Mon, 10 Sep 2012 18:33:26 Z</pubDate>
      <a10:updated>2012-09-10T15:35:13Z</a10:updated>
      <author>gurujx</author>
      <nasdaq:tickers>ESRX</nasdaq:tickers>
      <nasdaq:tickers>LIOX</nasdaq:tickers>
      <nasdaq:tickers>MAR</nasdaq:tickers>
      <nasdaq:tickers>PFIE</nasdaq:tickers>
      <nasdaq:tickers>SGEN</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/weekly-cfo-sells-highlight-sgen-pfie-mar-esrx-liox-rgen-cm171496</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/weekly-cfo-sells-highlight-sbac-xoxo-mth-fico-sgen-oas-cm169565">
      <guid isPermaLink="false">169565</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lMd76ggZD5A/weekly-cfo-sells-highlight-sbac-xoxo-mth-fico-sgen-oas-cm169565</link>
      <category>Investing</category>
      <title>WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS</title>
      <description>According to  GuruFocus Insider Data  , the largest CFO sells during the past week were: SBA Communications Corporation, XO Group Inc, Meritage Homes Corporation, Fair Isaac Corporation,&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/lMd76ggZD5A" height="1" width="1"/&gt;</description>
      <pubDate>Mon, 03 Sep 2012 18:36:27 Z</pubDate>
      <a10:updated>2012-09-03T15:35:24Z</a10:updated>
      <author>gurujx</author>
      <nasdaq:tickers>FICO</nasdaq:tickers>
      <nasdaq:tickers>MTH</nasdaq:tickers>
      <nasdaq:tickers>SBAC</nasdaq:tickers>
      <nasdaq:tickers>SGEN</nasdaq:tickers>
      <nasdaq:tickers>XOXO</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/weekly-cfo-sells-highlight-sbac-xoxo-mth-fico-sgen-oas-cm169565</feedburner:origLink></item>
  </channel>
</rss>
